Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

4405 results

Sort By:

LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Study ID: NCT05990465
Start Date: 2025-01
End Date: 2027-07
Study Type

Interventional

Study Phase

Phase1

No. of Participants

12

Intervention / Treatment

Pirtobrutinib

LV20.19 CAR T cells

Sponsor

Medical College of Wisconsin

Source: clinicaltrials.gov

Share:
Add to list

Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

Study ID: NCT06497465
Start Date: 2025-01-31
End Date: 2029-01-31
Study Type

Interventional

Study Phase

Phase3

No. of Participants

150

Intervention / Treatment

Dolutegravir 50mg Tab

Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]

Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)

Sponsor

Johns Hopkins University

Source: clinicaltrials.gov

Share:
Add to list

Inpatient Endoscopy Procedure Planning Delays and Impact on Length of Stay and 30-day Readmission

Study ID: NCT05798065
Start Date: 2025-04-01
End Date: 2025-06-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

3700

Intervention / Treatment

Inpatient gastrointestinal endoscopy

Sponsor

Radboud University Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Open Label Single Arm Pilot Trial of Letermovir for Cytomegalovirus Prophylaxis After Axicabtagene Ciloleucel Therapy

Study ID: NCT06575374
Start Date: 2024-12-31
End Date: 2027-08-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

36

Intervention / Treatment

Letermovir

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Study ID: NCT06406465
Start Date: 2024-11-26
End Date: 2028-07-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

Whiteness

Cisplatin

Etoposide

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera

Study ID: NCT06290765
Start Date: 2025-01-01
End Date: 2026-06-30
Study Type

Interventional

Study Phase

Phase4

No. of Participants

70

Intervention / Treatment

Ropeginterferon alfa-2b

Phlebotomy and aspirin

Sponsor

PharmaEssentia

Source: clinicaltrials.gov

Share:
Add to list

Impact of Traumatic Childbirth on Mother-baby Dyadic Interaction and Maternal Psychological Outcome: a Prospective Study

Study ID: NCT06587373
Start Date: 2025-01-02
End Date: 2026-07-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

Assessment of the quality of mother-child dyadic relationships

Sponsor

Besancon University Hospital Center

Source: clinicaltrials.gov

Share:
Add to list

SHR-1701 Combined with SHR2554 and BP102 for MCRC

Study ID: NCT06679673
Start Date: 2024-12
End Date: 2026-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

20

Intervention / Treatment

SHR-1701

BP102

SHR2554

Sponsor

Fudan University

Source: clinicaltrials.gov

Share:
Add to list

Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)

Study ID: NCT06280820
Start Date: 2024-11-26
End Date: 2034-04-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

2000

Intervention / Treatment
Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Source: clinicaltrials.gov

Share:
Add to list

Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research

Study ID: NCT06155565
Start Date: 2024-12
End Date: 2026-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

500

Intervention / Treatment
Sponsor

Power Life Sciences Inc.

Source: clinicaltrials.gov

Share:
Add to list